HUMALOG MIX 50 (KWIKPEN) SUSPENSION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

INSULIN LISPRO; INSULIN LISPRO PROTAMINE SUSPENSION

제공처:

ELI LILLY CANADA INC

ATC 코드:

A10AD04

INN (국제 이름):

INSULIN LISPRO

복용량:

50UNIT; 50UNIT

약제 형태:

SUSPENSION

구성:

INSULIN LISPRO 50UNIT; INSULIN LISPRO PROTAMINE SUSPENSION 50UNIT

관리 경로:

SUBCUTANEOUS

패키지 단위:

3ML/PEN

처방전 유형:

Schedule D

치료 영역:

INSULINS

제품 요약:

Active ingredient group (AIG) number: 0242161002; AHFS:

승인 상태:

MARKETED

승인 날짜:

2014-01-23

제품 특성 요약

_HUMALOG, HUMALOG 200 units/mL KwikPen, HUMALOG MIX25, HUMALOG MIX50 _
_Page 1 of 63 _
_ _
PRODUCT MONOGRAPH
HUMALOG
®
(insulin
lispro injection)
Solution
for Injection, 100 units/mL, Lilly Standard
ATC Code: A10AB04
fast-acting
HUMALOG
®
200 UNITS/ML KWIKPEN
®
(insulin
lispro injection)
Solution
for Injection, 200 units/mL, Lilly Standard
ATC Code: A10AB04
fast-acting
HUMALOG
® MIX25
®
(25% insulin
lispro injection,
75% insulin
lispro protamine suspension)
Suspension for Injection, 100 units/mL, Lilly Standard
ATC Code: A10AD04
intermediate- or long-acting combined with fast-acting
HUMALOG MIX50
®
(50% insulin
lispro injection,
50% insulin
lispro protamine suspension)
Suspension for Injection, 100 units/mL, Lilly Standard
ATC Code: A10AD04
intermediate- or long-acting combined with fast-acting
THERAPEUTIC CLASSIFICATION
Anti-Diabetic Agent
©Eli Lilly Canada Inc.
Exchange Tower
130 King Street West, Suite 900
P.O. Box 73
Toronto, Ontario
M5X 1B1
SUBMISSION CONTROL NO: 245846
DATE OF INITIAL APPROVAL:
October 8, 1996
DATE OF REVISION:
April 12, 2021
_HUMALOG, HUMALOG 200 units/mL KwikPen, HUMALOG MIX25, HUMALOG MIX50 _
_Page 2 of 63 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................4
WARNINGS AND PRECAUTIONS
.............................................................................5
ADVERSE
REACTIONS............................................................................................
11
DRUG INTERACTIONS
............................................................................................
12
DOSAGE AND ADMINISTRATION
.........................................................................
13
OVERDOSAGE
...........